Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.
The second trial site is at the Central Coast Local Health District in New South Wales.
It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.
Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.